A detailed history of Cornercap Investment Counsel Inc transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Cornercap Investment Counsel Inc holds 47,763 shares of LYEL stock, worth $52,539. This represents 0.02% of its overall portfolio holdings.

Number of Shares
47,763
Previous 96,288 50.4%
Holding current value
$52,539
Previous $139,000 53.24%
% of portfolio
0.02%
Previous 0.02%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$1.13 - $1.88 $54,833 - $91,227
-48,525 Reduced 50.4%
47,763 $65,000
Q2 2024

Aug 08, 2024

SELL
$1.3 - $3.01 $1,089 - $2,522
-838 Reduced 0.86%
96,288 $139,000
Q3 2023

Nov 13, 2023

BUY
$1.45 - $3.35 $140,832 - $325,372
97,126 New
97,126 $142,000
Q1 2023

May 11, 2023

BUY
$1.97 - $3.58 $177,638 - $322,815
90,172 New
90,172 $212,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $273M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Cornercap Investment Counsel Inc Portfolio

Follow Cornercap Investment Counsel Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cornercap Investment Counsel Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cornercap Investment Counsel Inc with notifications on news.